FDA Device Center Analyzes Why It Missed PMA Review Goals
This article was originally published in The Gray Sheet
FDA pre-market approval reviews tend to take longer when the medical officer leaves the review team, when clinical trial data issues arise and when companies engage in "excessive" back and forth with FDA during the review process, according to a recent FDA analysis.
You may also be interested in...
Members of the Senate HELP Committee expressed concerns that potential riders added to the FDA user fee bill could slow down passage and add more work for FDA staff.
Union of Concerned Scientists survey finds that many FDA scientists feel that business interests affect agency decisions. Nevertheless, a strong majority said that the agency is effectively protecting public health.
Pre-market review of device applications, among other core CDRH activities, would come to a virtual halt in the event of a federal government shutdown, according to Center Director Jeffrey Shuren.